Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT) and Roche Holding AG (OtherRHHVF)

TipRanks05:50 · Ratings

Sarepta Therapeutics Price Target Maintained With a $202.00/Share by Needham

Dow Jones02:45 · Ratings

Buy Rating Reaffirmed for Sarepta Therapeutics Following Positive EMBARK Study Results

TipRanks02:05 · Ratings

Leerink Partners Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating

Futu NewsJan 27 22:33 · Ratings

Sarepta Therapeutics Says Phase 3 Study of Potential Muscular Dystrophy Drug Shows 'Positive' Results

MT NewswiresJan 27 17:28

Sarepta's EMBARK Study Part 2 Results: ELEVIDYS Gene Therapy Shows Sustained Functional Gains And Disease Stabilization In Duchenne Muscular Dystrophy

BenzingaJan 27 14:30